Drugs play a central role in modern medicine, but bringing new ones to market is a lengthy, expensive process. Pharmaceutical companies are exploring ways to streamline all aspects of their complex pipelines with artificial intelligence (AI).
A key early step is the discovery and design of new molecules that have a desired biochemical effect that can modulate known disease-related processes. To succeed, the molecules must also be suitable for manufacture and drug formulation, and have an acceptably low number of side effects. Finding better candidates and eliminating losers at an early stage makes this process faster and cheaper.
No entries found
Log in to Read the Full Article
Sign in using your ACM Web Account username and password to access premium content if you are an ACM member, Communications subscriber or Digital Library subscriber.
Please select one of the options below for access to premium content and features.
Create a Web Account
If you are already an ACM member, Communications subscriber, or Digital Library subscriber, please set up a web account to access premium content on this site.
Join the ACM
Become a member to take full advantage of ACM's outstanding computing information resources, networking opportunities, and other benefits.
Subscribe to Communications of the ACM Magazine
Get full access to 50+ years of CACM content and receive the print version of the magazine monthly.
Purchase the Article
Non-members can purchase this article or a copy of the magazine in which it appears.